Proliferative potential and response to nivolumab in clear cell renal cell carcinoma patients.

Tian ZhangSarabjot PablaFelicia L LenzoJeffrey M ConroyMary K NeslineSean T GlennAntonios Papanicolau-SengosBlake BurgherVincent GiamoJonathan AndreasYirong WangWiam BsharaKatherine G MaddenKeisuke ShiraiKonstantin DragnevLaura J TafeRajan GuptaJason ZhuMatthew LabriolaShannon McCallDaniel J GeorgePooja GhataliaFarshid DayyaniRobert EdwardsMichelle S ParkRajbir SinghRobin JacobSaby GeorgeBo XuMatthew ZibelmanRazelle KurzrockCarl Morrison

Published in: Oncoimmunology (2020)

Cell proliferation has value in predicting response to nivolumab in clear cell mRCC patients, especially when combined with PD-L1 expression. Further studies which include the addition of progression-free survival (PFS) along with sufficiently powered subgroups are required to further support these findings.

Keyphrases

end stage renal disease
cell proliferation
ejection fraction
newly diagnosed
chronic kidney disease
free survival
prognostic factors
risk assessment
patient reported outcomes
cell cycle
signaling pathway